While common forms of arterial disease such as stroke and myocardial infarction are well studied and appropriate treatment algorithms are well described, occasionally, practitioners will encounter patients with thrombosis in other arteries; the cause and treatment of which is not entirely obvious or well studied. In this section, we will review the current data on arterial thrombosis, describing anatomic sources and hypercoagulable associations, and outline the epidemiology, pathophysiology, clinical presentation, etiology, and treatment of intracardiac thrombus, primary aortic mural thrombus, visceral infarctions, and cryptogenic limb ischemia. (Table 1) .
| INTRODUC TI ON TO ARTERIAL THROMBOS IS
While common forms of arterial disease such as stroke and myocardial infarction are well studied and appropriate treatment algorithms are well described, occasionally, practitioners will encounter patients with thrombosis in other arteries; the cause and treatment of which is not entirely obvious or well studied. In this section, we will review the current data on arterial thrombosis, describing anatomic sources and hypercoagulable associations, and outline the epidemiology, pathophysiology, clinical presentation, etiology, and treatment of intracardiac thrombus, primary aortic mural thrombus, visceral infarctions, and cryptogenic limb ischemia. (Table 1) .
| ARTERIAL THROMBOS IS-ANATOMIC CONS IDER ATIONS
Arterial thrombosis most often occurs in association with atherosclerosis. In cryptogenic cases, arterial thrombosis may result from an anatomic source, the most common of which is cardioembolic, such as intracardiac thrombus, atrial appendage thrombus, patent foramen ovale with paradoxical embolus, and valvular vegetation.
The minimal workup we consider in truly cryptogenic cases is assessment for a cardioembolic source ( Figure 1 ) including a transthoracic echocardiogram in conjunction with injection of agitated saline contrast and color Doppler imaging in order to detect a patent foramen ovale. Due to the unique nature of intracardiac thrombi and primary aortic mural thrombi, the following sections will outline the epidemiology, etiology, and management of these entities.
| INTR AC ARD IAC THROMB I
Left ventricular (LV) thrombus most commonly occur after myocardial infarction, particularly in cases of large anterior STEMI in the distribution of the left anterior descending coronary artery 1 ; however, hypereosinophilia remains an important cause documented in various case reports. 2 Anteroapical infarcts result in poor contraction of the LV muscle and stasis of intracavitary blood flow. This relative stasis of blood is thought to increase the risk of thrombus formation. One recent systematic review revealed the rate of LV thrombi in the postpercutaneous coronary intervention (PCI) era after all STEMI was 2.7% and 9.1% after anterior STEMI. 3 The major risk of 
LV thrombus in this setting is potential embolization before clot res- 
| PRIMARY AORTI C MUR AL THROMBUS
An aortic mural thrombus or mobile aortic thrombus is thrombus that appears to be nearly free floating, with the potential to cause a cerebral, visceral, or peripheral embolism. Often an aortic thrombus originates from an atherosclerotic aortic wall lesion or an aortic aneurysm, but occasionally a patient will have primary aortic mural thrombus (PAMT)-defined as thrombus attached to the aortic wall in the absence of any atherosclerotic or aneurysmal disease in the aorta. The incidence of thoracic aortic thrombi in cases of peripheral embolism is reported to be as high as 9%. 10 Most cases are clinically silent, only to be diagnosed after an embolic event, usually involving the extremities. 11 TEE remains the recommended diagnostic modality of choice 11 ; however, mural thrombi may be detected by CT angiography. 12 Due to the low incidence of mobile aortic thrombus, no therapeutic standard exists. Retrospective studies with limited patient numbers and case reports reveal F I G U R E 1 Assessment and workup of cryptogenic limb ischemia and visceral infarction a variety of approaches, including anticoagulation alone, aortic stenting, and surgical thrombectomy. 13 Successful treatment, defined as freedom from further embolic events or recurrence of thrombus, has been achieved with anticoagulation alone in isolated case reports 14 ; however, one meta-analysis seems to favor the surgical management of aortic mural thrombus in the normal or minimally diseased aorta due to the high recurrence rate of thrombus (26.4% vs 5.7%) when using anticoagulation as primary therapy compared to surgery. 15 Choukroun et al 11 suggest a strategy beginning with anticoagulation, followed by surgical thrombus removal only when anticoagulation alone is not effective. should also be considered as outlined in Figure 1 . Although it is worthwhile to describe predisposing factors and general causes of arterial thrombosis, it is also important to assess for specific sites of infarction as the management will change based on the visceral organ or limb as described below.
| ARTERIAL THROMBOS IS-HYPERCOAG UL AB LE CONS IDER ATIONS

| VISCER AL ARTERIAL THROMBOS IS
Visceral infarctions remain a rare and understudied clinical problem.
Much of the literature regarding these events is confined to retrospective studies, case series, and case reports, highlighting an area where future research is warranted. Based on review of this literature, the following sections will outline the epidemiology, presentation, etiology, and management of renal, mesenteric, adrenal, and splenic infarctions. with SMA occlusion, the superior mesenteric embolus to thrombus ratio was 1.4:1. 29 The incidence of acute mesenteric ischemia is approximately 1/1000 hospital admissions 30 and overall, females are affected 66%-70% of the time. 31, 32 Despite surgical advances, this remains a lethal condition with mortality of 60%-66% due in part to advanced presentation and multiple comorbidities. rates of mortality (36% vs 50%) in one single-center retrospective study. 38 Open repair and laparotomy is indicated for any signs of peritonitis and remains a good option for embolectomy. 39 Long-term management of patients with mesenteric ischemia focuses on aggressive risk factor modification, that is, smoking cessation, statin therapy, and blood pressure control. Lifelong aspirin is indicated in all patients and dual antiplatelet therapy (DAPT) is indicated for 1-3 months following endovascular repair. In patients with atrial fibrillation and inherited or acquired thrombophilia, lifelong anticoagulation is indicated. In patients with cryptogenic infarction, we also consider lifelong oral anticoagulation.
| RENAL INFARC TION
| ADRENAL INFARC TION
The adrenal gland contains a vascular network that is prone to thrombosis and hemorrhage in certain rare settings. Bilateral infarction of the adrenal gland generally presents with abdominal pain and acute adrenal insufficiency, which can occasionally be life-threatening. Meningococcal sepsis, particularly in younger patients, has classically been associated with acute bilateral adrenal hemorrhage and the development of purpura fulminans (the so-called WaterhouseFriderichsen Syndrome). 40 Outside of this setting, there are limited data on the associated causes, incidence and natural history of adrenal thrombosis, mostly limited to case series and case reports.
Antiphospholipid syndrome is a rare, but established cause of acute adrenal insufficiency. 41, 42 One review of acute adrenal insufficiency associated with antiphospholipid syndrome examined 86 cases, finding patients were generally young (mean age 43 years), with the majority presenting with abdominal pain (55%), hypotension (54%), and fever (40%); 36% of cases were fatal. 43 Heparin-induced thrombocytopenia is another prothrombotic condition that can provoke adrenal thrombosis and hemorrhage. 44 One series examined 17 cases of bilateral adrenal infarction provoked by Heparin-induced thrombocytopenia, noting overall mortality was high (27%), with 100% mortality in patients whose diagnosis was initially unrecognized. 
| S PLENI C INFARC TI ON
Splenic infarction occurs when the splenic artery or one of its subbranches becomes occluded with an embolus or thrombus. Splenic infarction is a rare event, accounting for only 0.016% of admissions at a single academic medical center over 10 years. 49 The presentation is variable; however, the most common clinical and laboratory features include left-sided abdominal pain (33%), nausea and vomiting (22%), fever and chills (27%), increased LDH (69%), and leukocytosis (58%) according to a study of 49 patients at a single emergency department. 50 Splenic infarction can occur in a variety of settings as evidenced by case series and reports, but the main causes include embolic, hypercoagulable states, hematologic disease associated with splenomegaly, infection, and cryptogenic. Cardiogenic emboli were the predominant etiology in two case series. 49, 51 Atrial fibrillation was common in these groups, although septic emboli from infective endocarditis remains a noteworthy source of infarction. 52 The most commonly cited hypercoagulable state associated with splenic infarction was antiphospholipid antibody syndrome, especially in younger patients. 49, 50, 53 Hematologic diseases including myeloproliferative neoplasms such as polycythemia vera, 54 chronic myelogenous leukemia, 55 and myelofibrosis have also been implicated in splenic infarction. Based on a retrospective analysis of splenic infarction over 10 years, Wand et. al concluded that routine evaluation for myeloproliferative neoplasms, including testing for the JAK V617F mutation should be considered, especially in the presence of thrombocytosis in the workup of cryptogenic splenic infarction. 53 Small, repetitive splenic infarcts are common in patients with sicklecell anemia and have been documented in those with sickle-cell trait. 56 In addition to hemoglobinopathies directly causing splenic infarction, they have also been shown to indirectly predispose patients infected with Epstein Barr virus to infarction due to the congestion associated with acute splenic enlargement. 57, 58 Given the spectrum of splenic infarction etiologies, there exists no consensus regarding its diagnostic approach or its management. A practical approach would be to order CT, ECG, echocardiography studies as well as blood cultures in all cases with consideration of APS in young patients and malignancy in older patients. 53 Initial treatment of splenic infarction is generally conservative and directed at the precipitating factors. Many patients will make a full recovery with supportive care and anticoagulation. Therapies directed at vaso-occlusion without anticoagulation are indicated in those with sickle-cell disease.
Surgical treatment will only be necessary in the presence of complications (hemorrhage, abscess, or pseudocyst) and in massive infarction when symptoms persist. 59 In cryptogenic splenic infarction, we consider indefinite anticoagulation with the goal of preventing recurrent visceral infarction.
| CRYP TOG ENI C ACUTE LIMB ISCHEMIA
Acute limb ischemia (ALI) is the sudden and critical loss of extremity perfusion, with symptoms lasting < 2 weeks. 60 The incidence of this condition is approximately 500-1000 per million/year in the European and North American population. 61 Symptoms develop over a period of hours to days and range from new or worsening intermittent claudication to lower extremity pain at rest, paresthesias, muscle weakness, and paralysis of the affected limb. 60 While the majority of ALI results from progression of chronic limb ischemia, embolization of a proximal thrombus, or thrombus formation in the setting of trauma, rarely the practitioner will encounter patients with ALI with no obvious cause. In such patients with cryptogenic acute limb ischemia (cALI), no standard management algorithm exists. It is reasonable to mirror current guidelines which suggest pursuit of a diagnostic workup to identify a potential cardioembolic source (occult arrhythmia, cardiac abnormality) or other precipitant 62 and to consider an acquired thrombophilia and/or vasculitis workup in the absence of a provoked etiology.
In one retrospective study, the role of thrombophilia in Chinese patients with premature peripheral arterial obstructive disease (PAOD) found thrombophilia played a role in 38% of cases with the most common etiologies related to Takayasu arteritis (6.7%), systemic vasculitis (4.7%), and antiphospholipid syndrome (APS;
3.3%). 63 Guidelines regarding immediate therapy for ALI are well established 64 ; however, well-powered, prospective studies regarding long-term management of patients with cALI remain to be seen. Our group performed a retrospective analysis of patients with cALI and found the overall rate of recurrence to be 25%. 65 In patients with ALI where a cause could be identified, recurrence occurred in 17% despite 40% being therapeutically anticoagulated at the time of representation. 65 Given the high recurrence rate, it would be reasonable to consider indefinite anticoagulation with warfarin or a direct oral anticoagulant (DOAC) for the purposes of secondary prevention in cALI. 
| CON CLUS ION
